Back to top
more

IntraCellular Therapies (ITCI)

(Delayed Data from NSDQ)

$86.17 USD

86.17
713,064

-0.37 (-0.43%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $86.22 +0.05 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe

by Zacks Equity Research

Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.

Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.

Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

by Zacks Equity Research

Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.

Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues beat estimates.

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Seer, Inc. (SEER) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Seer, Inc. (SEER) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Intra-Cellular Therapies (ITCI) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly

by Zacks Equity Research

United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.

Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.

Ekta Bagri headshot

3 Drug Stocks Most Wall Street Analysts Are Bullish About

by Ekta Bagri

Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how DICE Therapeutics, Inc. (DICE) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.

Can Intra-Cellular (ITCI) Climb 33% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 32.7% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in several other indications.

Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?

by Zacks Equity Research

On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.

How Much Upside is Left in Intra-Cellular (ITCI)? Wall Street Analysts Think 33%

by Zacks Equity Research

The consensus price target hints at a 33.5% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now

by Zacks Equity Research

Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Intra-Cellular (ITCI) This Earnings Season?

by Zacks Equity Research

Intra-Cellular (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -12.66% and 58.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?